RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study

To evaluate the efficacy and safety of 2 dosing regimens of ranibizumab 0.5 mg versus verteporfin photodynamic therapy in Asian patients with visual impairment due to myopic choroidal neovascularization. METHODS: Eligible patients (aged ≥18 years) were randomized 2:2:1 to Group I (n = 182; ranibizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Youxin, Sharma, Tarun, Li, Xiaorong, Song, Yanping, Chang, Qing, Lin, Renxin, Egger, Anna, Foo, Arthur, Gekkieva, Margarita, Lai, Timothy Y. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2019
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768610/
https://www.ncbi.nlm.nih.gov/pubmed/30204730
http://dx.doi.org/10.1097/IAE.0000000000002292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768610/
https://www.ncbi.nlm.nih.gov/pubmed/30204730
http://dx.doi.org/10.1097/IAE.0000000000002292

Ejemplares similares